Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Isabel Leroux-Roels & Geert Leroux-Roels. (2009) Current status and progress of prepandemic and pandemic influenza vaccine development. Expert Review of Vaccines 8:4, pages 401-423.
Read now
Read now
Articles from other publishers (17)
Aref SepasiMehri GhafourianMorteza TaghizadehMehdi Mahdavi. (2023) Formulation of Recombinant H1N1 Hemagglutinin in MF59 and Alum Adjuvants: A Comparison of the Vaccines Potency and Efficacy in BALB/C Mice. Viral Immunology 36:6, pages 401-408.
Crossref
Crossref
Ozlem Bulut, Gizem Kilic, Jorge Domínguez-Andrés & Mihai G Netea. (2020) Overcoming immune dysfunction in the elderly: trained immunity as a novel approach. International Immunology 32:12, pages 741-753.
Crossref
Crossref
Pornthep Chanthavanich, Edwin Anderson, Phirangkul Kerdpanich, Michael Bulitta, Niranjan Kanesa-thasan & Matthew Hohenboken. (2019) Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects. Pediatric Infectious Disease Journal 38:7, pages 757-764.
Crossref
Crossref
Joseph R. FrancicaDaniel E. ZakCaitlyn LindeEmilio SienaCarrie JohnsonMichal JuraskaNicole L. YatesBronwyn GunnEnnio De GregorioBarbara J. FlynnNicholas M. ValiantePadma MalyalaSusan W. BarnettPampi SarkarManmohan SinghSiddhartha JainMargaret Ackerman, Munir AlamGuido FerrariAndres Salazar, Georgia D. TomarasDerek T. O’HaganAlan AderemGalit AlterRobert A. Seder. (2017) Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. Blood Advances 1:25, pages 2329-2342.
Crossref
Crossref
Sharon E. Frey, Mari Rose Aplasca-De Los Reyes, Humberto Reynales, Nancy Nazaire Bermal, Uwe Nicolay, Vas Narasimhan, Eduardo Forleo-Neto & Ashwani Kumar Arora. (2014) Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine 32:39, pages 5027-5034.
Crossref
Crossref
Motoyasu Onishi, Mitsutaka Kitano, Keiichi Taniguchi, Tomoyuki Homma, Masanori Kobayashi, Akihiko Sato, Cevayir Coban & Ken J. Ishii. (2014) Hemozoin is a potent adjuvant for hemagglutinin split vaccine without pyrogenicity in ferrets. Vaccine 32:25, pages 3004-3009.
Crossref
Crossref
Birgit Weinberger, Michael Schirmer, Raffaella Matteucci Gothe, Uwe Siebert, Dietmar Fuchs & Beatrix Grubeck-Loebenstein. (2013) Recall Responses to Tetanus and Diphtheria Vaccination Are Frequently Insufficient in Elderly Persons. PLoS ONE 8:12, pages e82967.
Crossref
Crossref
Gunnveig Grodeland, Siri Mjaaland, Kenneth H. Roux, Agnete Brunsvik Fredriksen & Bjarne Bogen. (2013) DNA Vaccine that Targets Hemagglutinin to MHC Class II Molecules Rapidly Induces Antibody-Mediated Protection against Influenza. The Journal of Immunology 191:6, pages 3221-3231.
Crossref
Crossref
J. Puig-Barberà, A. Natividad-Sancho, J. Calabuig-Pérez, J.A. Lluch-Rodrigo, E. Pastor-Villalba, S. Martínez-Úbeda, S. Pérez-Vilar & J. Díez-Domingo. (2013) MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: Comparative effectiveness using the Valencia health care information system. Vaccine 31:37, pages 3995-4002.
Crossref
Crossref
Christoph Hatz, Frank von Sonnenburg, Daniela Casula, Maria Lattanzi & Geert Leroux-Roels. (2012) A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. Vaccine 30:23, pages 3470-3477.
Crossref
Crossref
Anneke Steens, Eleonora G Wijnans, Jeanne P Dieleman, Miriam CJM Sturkenboom, Marianne AB van der Sande & Wim van der Hoek. (2011) Effectiveness of a MF-59™-adjuvanted pandemic influenza vaccine to prevent 2009 A/H1N1 influenza-related hospitalisation; a matched case-control study. BMC Infectious Diseases 11:1.
Crossref
Crossref
Bruce Y. Lee, Randy M. Stalter, Kristina M. Bacon, Julie H.Y. Tai, Rachel R. Bailey, Shanta M. Zimmer & Michael M. Wagner. (2011) Cost-Effectiveness of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Adult Hemodialysis Patients. American Journal of Kidney Diseases 57:5, pages 724-732.
Crossref
Crossref
Timo VesikariAino KarvonenSandrine TilmanAstrid Borkowski, Emanuele Montomoli, Angelika BanzhoffRalf Clemens. (2010) Immunogenicity and Safety of MF59-Adjuvanted H5N1 Influenza Vaccine From Infancy to Adolescence. Pediatrics 126:4, pages e762-e770.
Crossref
Crossref
Joan Puig-Barberà. (2009)
MF59
®
-adjuvanted seasonalinfluenza vaccine
. Aging Health 5:4, pages 475-481.
Crossref
Crossref
Arnold S. Monto, Filippo Ansaldi, Richard Aspinall, Janet E. McElhaney, Luis F. Montaño, Kristin L. Nichol, Joan Puig-Barberà, Joe Schmitt & Iain Stephenson. (2009) Influenza control in the 21st century: Optimizing protection of older adults. Vaccine 27:37, pages 5043-5053.
Crossref
Crossref
Velio Bocci, Valter Travagli & Iacopo Zanardi. (2009) The failure of HIV vaccines: A new autovaccine may overcome some problems. Medical Hypotheses 72:6, pages 662-664.
Crossref
Crossref
Derek T. O’Hagan & Audino Podda. 2008. Influenza Vaccines for the Future. Influenza Vaccines for the Future
221
244
.